Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 8
Submit an article Journal homepage
7,453
Views
51
CrossRef citations to date
0
Altmetric
Review

Measles elimination: progress, challenges and implications for rubella control

Felicity T Cutts London School of Hygiene and Tropical Medicine. Keppel St, London WC1E 7HT, UK. [email protected]; London School of Hygiene and Tropical Medicine. Keppel St, London WC1E 7HT, UK. [email protected]
,
Justin Lessler Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
&
Charlotte JE Metcalf Department of Zoology, Oxford University, Oxford, UK; Department of Zoology, Oxford University, Oxford, UK
Pages 917-932 | Published online: 09 Jan 2014

References

  • Clements CJ, Strassburg M, Cutts FT, Torel C. The epidemiology of measles. World Health Statistics Quarterly. Rap. Trimestriel de Statistiques Sanitaires Mondiales 45(2–3), 285 (1992).
  • World Health Organization. Measles – Progress towards global control and regional elimination, 1990–1998. Wkly. Epidemiol. Rec. 73, 389–396 (1998).
  • Foster A, Sommer A. Corneal ulceration, measles, and childhood blindness in Tanzania. Br. J. Ophthalmol. 71, 331–343 (1987).
  • Moss WJ, Griffin DE. Measles. Lancet 379, 153–164 (2012).
  • Simons E, Ferrari M, Fricks J et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 379(9832), 2173–2178 (2012).
  • Moss WJ, Strebel P. Biological feasibility of measles eradication. J. Infect. Dis. 204(Suppl. 1), S47–S53 (2011).
  • De Quadros CA, Andrus JK, Danovaro-Holliday MC, Castillo-Solórzano C. Feasibility of global measles eradication after interruption of transmission in the Americas. Expert Revi. Vaccines 7(3), 355–362 (2008).
  • Cooper LZ. The history and medical consequences of rubella. Rev. Infect. Dis. 7, S2–S10 (1985).
  • Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 320(8302), 781–784 (1982).
  • Gregg NM. Congenital cataract following German measles in the mother. Transact. Ophthalmol. Soc. Australia 3, 31–46 (1941).
  • Cutts FT, Vynnycky E. Modelling the incidence of congenital rubella syndrome in developing countries. Int. J. Epidemiol. 28, 1176–1184 (1999).
  • Vynnycky E, Adams EJ, Cutts FT et al. Using seroprevalence and immunisation coverage data to estimate the global burden of Congenital Rubella Syndrome, 1996–2010. (Submitted).
  • Plotkin SA. The history of rubella and rubella vaccination leading to elimination. Clin. Infect. Dis. 43(Suppl. 3), S164–S168 (2006).
  • Omer SB, Hiremath GS, Halsey NA. Respiratory administration of measles vaccine. Lancet 375, 706–708 (2010).
  • Díaz-Ortega JL, Bennett JV, Castañeda D, Martinez D, De Castro JF. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route. Vaccine 28, 7228–7232 (2010).
  • Simon JK, Ramirez K, Cuberos L et al. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clin. Vaccine Immunol. 18, 355–361 (2011).
  • Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: a review. Biologicals 25, 323–338 (1997).
  • Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 26, 383–398 (2008).
  • Sabin AB. Immunization against measles by aerosol. Rev. Infect. Dis. 5, 514–523 (1983).
  • Dilraj A, Cutts FT, De Castro JF et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 355, 798–803 (2000).
  • Dilraj A, Sukhoo R, Cutts FT, Bennett JV. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Vaccine 25, 4170–4174 (2007).
  • Bennett JV, Fernandez De Castro J, Valdespino-Gomez JL. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull. World Health Organ. 80, 806–812 (2002).
  • Wong-Chew RM, García-León ML, Espinosa-Torres Torrija B et al. Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. J. Infect. Dis. 204, 426–432 (2011).
  • Garrison LPJ, Bauch CT, Bresnahan BW, Hazlet TK, Kadiyala S, Veenstra DL. Using cost–effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. J. Infect. Dis. 204, S124–S132 (2011).
  • Higginson D, Theodoratou E, Nair H et al. An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children. BMC Public Health 11(Suppl. 3), S31 (2011).
  • World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, November 2012 – conclusions and recommendations. Wkly. Epidemiol. Rec. 88, 1–16 (2013).
  • World Health Organization. Mumps virus vaccines. WHO position paper. Wkly. Epidemiol. Rec. 82, 49–60 (2007).
  • Moss WJ, Scott S. The immunological basis for immunization series: module 7: measles – Update 2009. World Health Organization (2009).
  • Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J. Infect. Dis. 204(Suppl. 1), S133–S149 (2011).
  • Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 25(34), 6296–6304 (2007).
  • Orenstein W, Markowitz L, Preblud S, Hinman A, Tomasi A, Bart KJ. Appropriate age for measles vaccination in the United States. Dev. Biol. Stand. 65, 13 (1986).
  • De Serres G, Boulianne N, Meyer F, Ward BJ. Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months. Epidemiol. Infect. 115, 315–323 (1995).
  • World Health Organization. Measles vaccines: WHO position paper. Wkly. Epidemiol. Rec. 84(35), 349–360 (2009).
  • World Health Organization. Expanded Programme on Immunization. Measles immunization. Wkly. Epidemiol. Rec. 54, 337–339 (1979).
  • Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin. Infect. Dis. 29(1), 106–112 (1999).
  • Helfand RF, Witte D, Fowlkes A et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J. Infect. Dis. 198(10), 1457–1465 (2008).
  • Fowlkes A, Witte D, Beeler J et al. Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi. J. Infect. Dis. 204(Suppl. 1), S149–S157 (2011).
  • Helfand RF, Moss WJ, Harpaz R, Scott S, Cutts F. Evaluating the impact of the HIV pandemic on measles control and elimination. Bull. World Health Organ. 83(5), 329–337 (2005).
  • Scott S, Mossong J, Moss WJ, Cutts FT, Cousens S. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. Int. J. Epidemiol. 37(2), 356–367 (2008).
  • Rainwater-Lovett K, Moss WJ. Immunologic basis for revaccination of HIV-infected children receiving HAART. Fut. Virol. 6(1), 59–71 (2011).
  • Robertson S, Cutts F, Samuel R, Diaz-Ortega J. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella. Bull. World Health Organ. 75(1), 69 (1997).
  • Reef SE, Plotkin SA. Rubella vaccine. In: Vaccines (6th edition). Plotkin SA, Orenstein WA, Offit PA. (Eds). Elsevier Saunders 688–717 (2012).
  • Markowitz LE, Preblud SR, Fine PEM, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediat. Infect. Dis. J. 9(2), 101–110 (1990).
  • Boué A, Nicolas A, Montagnon B. Reinfection with rubella in pregnant women. Lancet 297(7712), 1251–1253 (1971).
  • Morgan Capner P, Rodeck C, Nicolaides K, Cradock Watson J. Prenatal detection of rubella specific IgM in fetal sera. Prenat. Diagn. 5(1), 21–26 (1985).
  • Hinman AR, Irons B, Lewis M, Kandoloa K. Economic analyses of rubella and rubella vaccines: a global review. Bull. World Health Organ. 80(4), 264–270 (2002).
  • Cutts F, Robertson S, Diaz-Ortega J, Samuel R. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: Burden of disease from CRS. Bull. World Health Organ. 75(1), 55 (1997).
  • Lawn JE, Reef S, Baffoe-Bonnie B, Adadevoh S, Caul EO, Griffin GE. Unseen blindness, unheard deafness, and unrecorded death and disability: congenital rubella in Kumasi, Ghana. Am. J. Public Health 90, 1555–1561 (2000).
  • Strebel PM, Gacic-Dobo M, Reef S, Cochi SL. Global use of rubella vaccines, 1980–2009. J. Infect. Dis. 204, S579–S584 (2011).
  • World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, April 2011 – conclusions and recommendations. Wkly. Epidemiol. Rec. 86, 205–220 (2011).
  • World Health Organization. Rubella vaccines: WHO position paper. Wkly. Epidemiol. Rec. 86, 301–316 (2011).
  • De Quadros C, Andrus J, Danovaro C, Castillo-Solorzano C. Is global measles eradication feasible: five years after the interruption of endemic measles transmission in the Americas. Expert Rev. Vaccines 7(3), 355–362 (2008).
  • Andrus JK, De Quadros CA, Castillo Solórzano C, Roses Periago M, Henderson D. Measles and rubella eradication in the Americas. Vaccine S4, D91–D96 (2011).
  • Burki T. GAVI alliance to roll out rubella vaccine. Lancet Infect. Dis. 12, 15–16 (2012).
  • Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J. Infect. Dis. 189, S27 (2004).
  • Grais RF, Ferrari M, Dubray C et al. Estimating transmission intensity for a measles epidemic in Niamey, Niger: lessons for intervention. Trans. R. Soc. Trop. Med. Hyg. 100(9), 867–873 (2006).
  • Fine PEM. Herd immunity: history, theory, practice. Epidemiol. Rev. 15(2), 265–302 (1993).
  • Cutts FT, Abebe A, Messele T et al. Sero-epidemiology of rubella in the urban population of Addis Ababa, Ethiopia. Epidemiol. Infect. 124, 467–479 (2000).
  • Farrington C, Whitaker H. Estimation of effective reproduction numbers for infectious diseases using serological survey data. Biostatistics 4(4), 621–632 (2003).
  • Mclean AR, Anderson RM. Measles in developing countries. Part I: epidemiological parameters and patterns. Epidemiol. Infect. 100, 111–133 (1988).
  • Chen RT, Weierbach R, Bisoffi Z et al. A ‘post-honeymoon period’ measles outbreak in Muyinga sector, Burundi. Int. J. Epidemiol. 23(1), 185–193 (1994).
  • World Health Organization. Monitoring progress towards measles elimination. Wkly. Epidemiol. Rec. 85, 489–496 (2010).
  • Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J. Infect. Dis. 189(Suppl. 1), S1–S3 (2004).
  • Gustafson TL, Lievens AW, Brunell PA, Moellenberg RG, Buttery C, Sehulster LM. Measles outbreak in a fully immunized secondary-school population. N. Engl. J. Med. 316(13), 771 (1987).
  • Markowitz LE, Preblud SR, Orenstein WA et al. Patterns of transmission in measles outbreaks in the United States, 1985–1986. N. Engl. J. Med. 320(2), 75–81 (1989).
  • Robertson SE, Markowitz LE, Berry DA, Dini EF, Orenstein WA. A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy. Public Health Rep. 107(1), 24 (1992).
  • Centers for Disease Control and Prevention. Measles prevention: recommendations of the Immunization Practices Advisory Committee. MMWR. 38(S9), 1–13 (1989).
  • Centers for Disease Control and Prevention. Achievements in Public Health: Elimination of Rubella and Congenital Rubella Syndrome – United States, 1969–2004. MMWR. 54, 279–282 (2005).
  • Gindler J, Tinker S, Markowitz L, Atkinson W, Dales L, Papania M. Acute measles mortality in the United States, 1987–2002. J. Infect. Dis. 189(Suppl. 1), S69–S77 (2004).
  • National Vaccine Advisory Committee. The measles epidemic: the problem, barriers and recommendations. JAMA. 266, 1547–1552 (1991).
  • Centers for Disease Control and Prevention. Status report on the Childhood Immunization Initiative: national, state, and urban area vaccination coverage levels among children aged 19–35 months – United States, 1996. MMWR. 46, 657–664 (1997).
  • Biellik R, Madema S, Taole A et al. First 5 years of measles elimination in southern Africa: 1996–2000. Lancet 359(9317), 1564–1568 (2002).
  • Baliraine FN, Bwogi J, Bukenya H et al. Possible interruption of measles virus transmission, Uganda, 2006–2009. Emerg. Infect. Dis. 17(1), 110 (2011).
  • World Health Organization. Measles outbreaks and progress towards meeting measles pre-elimination goals: WHO African Region, 2009–2010. Wkly. Epidemiol. Rec. 86, 129–140 (2011).
  • Cutts FT, Henderson RH, Clements CJ, Chen RT, Patriarca PA. Principles of measles control. Bull World Health Organ. 69(1), 1–7 (1991).
  • Goodson JL, Masresha BG, Wannemuehler K, Uzicanin A, Cochi S. Changing epidemiology of measles in Africa. J Infect Dis. 204(Suppl. 1), S205–214 (2011).
  • Minetti A, Kagoli M, Katsulukuta A et al. Lessons and challenges for measles control from unexpected large outbreak, Malawi. Emerg. Infect. Dis. 19(2), 202 (2013).
  • Naouri B, Ahmed H, Bekhit R, Teleb N, Mohsni E, Alexander Jr JP. Progress toward measles elimination in the eastern Mediterranean region. J. Infect. Dis. 204(Suppl. 1), S289–S298 (2011).
  • World Health Organization. Measles – Horn of Africa, 2010–2011. Wly Epidemiol. Rec. 87, 329–336 (2012).
  • Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect. Dis. 8(12), 796–803 (2008).
  • Martin R, Wassilak S, Emiroglu N et al. What will it take to achieve measles elimination in the World Health Organization European Region: progress from 2003–2009 and essential accelerated actions. J. Infect. Dis. 204(Suppl. 1), S325–S334 (2011).
  • Georgakopoulou T, Grylli C, Kalamara E, Katerelos P, Spala G, Panagiotopoulos T. Current measles outbreak in Greece. Euro Surveill 11(2), E060223 (2006).
  • Filia A, Curtale F, Kreidl P et al. Cluster of measles cases in the Roma/Sinti population, Italy, June–September 2006. Eur. Surveill. 11(10), E061012 (2006).
  • Seguliev Z, Duric P, Petrovic V et al. Current measles outbreak in Serbia: a preliminary report. Euor Surveill. 12(11), 3155 (2007).
  • Muscat M, Bang H, Wohlfahrt J, Glismann S, Mølbak K. Measles in Europe: an epidemiological assessment. Lancet 373(9661), 383–389 (2009).
  • Muscat M. Who gets measles in Europe? J. Infect. Dis. 204(Suppl. 1), S353–S365 (2011).
  • Ghebrehewet S, Hayhurst G, Keenan A, Moore H. Outbreak of measles in central and eastern Cheshire, UK, October 2008–February 2009. Epidemiol. Infect. 1(1), 1–8 (2012).
  • Kremer JR, Brown KE, Jin L et al. High genetic diversity of measles virus, World Health Organization European region, 2005–2006. Emerg. Infect. Dis. 14(1), 107 (2008).
  • Cortés JMM, Morilla EP, García VG et al. Measles outbreak in Andalusia, Spain, January to August 2011. Euro Surveill 17(42), 15 pii:20300 (2012).
  • Velicko I, Müller LL, Pebody R et al. Nationwide measles epidemic in Ukraine: the effect of low vaccine effectiveness. Vaccine 26, 6980–6985 (2008).
  • World Health Organization. Progress in global control and regional elimination of measles, 2000–2011. Wkly. Epidemiol. Rec. 88, 29–36 (2013).
  • Sniadack DH, Mendoza-Aldana J, Huyen DTT et al. Epidemiology of a measles epidemic in Vietnam 2008–2010. J. Infect. Dis. 204(Suppl. 1), S476–S482 (2011).
  • Sniadack DH, Mendoza-Aldana J, Jee Y, Bayutas B, Lorenzo-Mariano KM. Progress and challenges for measles elimination by 2012 in the Western Pacific Region. J. Infect. Dis. 204(Suppl. 1), S439–S446 (2011).
  • Wairagkar N, Chowdhury D, Vaidya S et al. Molecular epidemiology of measles in India, 2005–2010. J. Infect. Dis. 204(Suppl. 1), S403–S413 (2011).
  • Murhekar MV, Hutin YJ, Ramakrishnan R et al. The heterogeneity of measles epidemiology in India: implications for improving control measures. J. Infect. Dis. 204(Suppl. 1), S421–S426 (2011).
  • Weldegebriel GG, Gasasira A, Harvey P et al. Measles resurgence following a nationwide measles vaccination campaign, 2005–2008. J. Infect. Dis. 204(Suppl. 1), S226–S231 (2011).
  • Yaméogo KR, Perry RT, Yaméogo A et al. Migration as a risk factor for measles after a mass vaccination campaign, Burkina Faso, 2002. Int. J. Epidemiol. 34(3), 556–564 (2005).
  • Ettarh RR, Mutua MK, Kyobutungi C. Ethnicity and delay in measles vaccination in a nairobi slum. Trop. Med. Health 40(2), 59 (2012).
  • Marinova L, Muscat M, Kojouharova M, Mihneva Z, Kojouharova M. An update on an ongoing measles outbreak in Bulgaria, April–Nov 2009. Euro Surveillance 14(50)(2009).
  • Toole MJ, Waldman RJ. The public health aspects of complex emergencies and refugee situations. Ann. Rev. Public Health 18(1), 283–312 (1997).
  • Guerrier G, Zounoun M, Delarosa O et al. Malnutrition and mortality patterns among internally displaced and non-displaced population living in a camp, a village or a town in Eastern Chad. PloS One 4(11), e8077 (2009).
  • World Health Organization. Progress towards reducing measles mortality and eliminating measles, WHO eastern Mediterranean Region, 1997–2007. Wkly. Epidemiol. Rec. 83, 97–104 (2008).
  • Hu X, Xiao S, Chen B, Sa Z. Gaps in the 2010 measles SIA coverage among migrant children in Beijing: evidence from a parental survey. Vaccine 30, 5721–5725 (2012).
  • World Health Organization. Global reductions in measles mortality 2000–2008 and the risk of measles resurgence. Wkly Epidemiol. Rec. 49, 505–516 (2009).
  • Lessler J, Lowther SA, Moss WJ, Cummings DA. Maintaining high rates of measles immunization in Zambia. Epidemiol. Infect. 5, 1–11 (2010).
  • Bauch CT, Szusz E, Garrison LP. Scheduling of measles vaccination in low-income countries: projections of a dynamic model. Vaccine 27, 4090–4098 (2009).
  • World Health Organization. Progress in measles control: Kenya, 2002–2007. Wly Epidemiol. Rec. 82, 329–336 (2007).
  • Masresha BG, Fall A, Eshetu M et al. Measles mortality reduction and pre-elimination in the African region, 2001–2009. J. Infect. Dis. 204, S198–S204 (2011).
  • Cutts FT, Zell ER, Mason D, Bernier RH, Dini EF, Orenstein WA. Monitoring progress toward US preschool immunization goals. JAMA 267(14), 1952–1955 (1992).
  • Cutts FT, Izurieta H, Rhoda D. Measuring coverage in maternal and child health: design, implementation, and interpretation challenges associated with tracking vaccination coverage using household surveys. PloS Med. 10(5), e1001404 (2013).
  • Mbabazi WB, Nanyunja M, Makumbi I et al. Achieving measles control: lessons from the 2002–06 measles control strategy for Uganda. Health policy and planning 24(4), 261–269 (2009).
  • Osborne K, Weinberg J, Miller E. The European Sero-Epidemiology Network. Euro Surveillance 2(4), 29–31 (1997).
  • Gay N, Ramsay M, Cohen B et al. The epidemiology of measles in England and Wales since the 1994 vaccination campaign. Commun. Dis. Rep. CDR Rev. 7(2), R17 (1997).
  • Lowther SA, Curriero FC, Kalish BT, Shields TM, Monze M, Moss WJ. Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey. Lancet 373(9668), 1025–1032 (2009).
  • Nigatu W, Samuel D, Cohen B et al. Evaluation of a measles vaccine campaign in Ethiopia using oral-fluid antibody surveys. Vaccine 26(37), 4769–4774 (2008).
  • Ohuma E, Okiro E, Bett A et al. Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models. Epidemiol. Infect. 137(2), 227–233 (2009).
  • Babad H, Nokes DJ, Gay N, Miller E, Morgan-Capner P, Anderson R. Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options. Epidemiol. Infect. 114(2), 319–344 (1995).
  • Andrews N, Tischer A, Siedler A et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bull. World Health Organ. 86(3), 197–204 (2008).
  • Cairns KL, Perry RT, Ryman TK, Nandy RK, Grais RF. outbreak response immunization be recommended for measles outbreaks in middle-and low-income countries? An update. J. Infect. Dis. 204(Suppl. 1), S35–S46 (2011).
  • Luquero FJ, Pham-Orsetti H, Cummings DA et al. A long-lasting measles epidemic in Maroua, Cameroon 2008–2009: mass vaccination as response to the epidemic. J. Infect. Dis. 204, S243–S251 (2011).
  • Goodson JL, Wiesen E, Perry RT et al. Impact of measles outbreak response vaccination campaign in Dar es Salaam, Tanzania. Vaccine 27(42), 5870–5874 (2009).
  • World Health Organization. Progress in global measles control, 2000–2010. Wkly. Epidemiol. Rec. 87(5), 45–52 (2012).
  • Metcalf CJE, Lessler J, Klepac P, Cutts FT, Grenfell BT. Minimum levels of coverage needed for rubella vaccination: impact of local demography, seasonality and population heterogeneity. Epidemiology and Infection 16, 1–12 (2012).
  • World Health Organization. Rubella Vaccine: WHO position paper. Wkly. Epidemiol. Rec. 75, 161–172 (2000).
  • Morice A, Carvajal X, Leon M et al. Accelerated rubella control and congenital rubella syndrome prevention strengthen measles eradiction: the Costa Rican experience. J. Infect. Dis. 187, S158–S163 (2003).
  • Metcalf CJE, Munayco CV, Chowell G, Grenfell BT, Bjørnstad ON. Rubella meta-population dynamics and importance of spatial coupling to the risk of congenital rubella syndrome in Peru. J. R. Soc. Interface 8, 369–376 (2011).
  • Metcalf CJ, Cohen C, Lessler J et al. Implications of spatially heterogeneous vaccination coverage for the risk of congenital rubella syndrome in South Africa. J. R. Soc. Interface 10(78), 20120756 (2013).
  • Zimmerman LA, Muscat M, Jankovic D et al. Status of Rubella and Congenital Rubella Syndrome Surveillance, 2005–2009, the World Health Organization European Region. J. Infect. Dis. 204(Suppl. 1), S381–S388 (2011).
  • Muscat M, Zimmerman L, Bacci S et al.; Toward rubella elimination in Europe: an epidemiological assessment. Vaccine 30, 1999–2007 (2012).
  • Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, Mcfarland JW, Hersh BS. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369, 191–200 (2007).
  • De Quadros C, Hersh B, Nogueira A, Carrasco P, Da Silveira CM. Measles eradication: experience in the Americas. Bull. World Health Organ. 76(Suppl. 2), 47 (1998).
  • Izurieta H, Venczel L, Dietz V et al. Monitoring measles eradication in the region of the Americas: critical activities and tools. J. Infect. Dis. 187(Suppl. 1), S133–S139 (2003).
  • Dietz V, Venczel L, Izurieta H et al. Assessing and monitoring vaccination coverage levels: lessons from the Americas. Rev. Panam. Salud Publica 16(6), 432–442 (2004).
  • Rani M, Yang B, Nesbit R. Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications. Bull. World Health Organ. 87, 707–713 (2009).
  • Ferrari MJ, Grenfell BT, Strebel PM. Think globally, act locally: the role of local demographics and vaccination coverage in the dynamic response of measles infection to control. Philos. Trans. R. Soc. London B doi:10.1098/rstb.2012.0141 (2013) (Epub ahead of print).
  • Lim SS, Stein DB, Charrow A, Murray CJL. Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage. Lancet 372(9655), 2031–2046 (2008).
  • Featherstone DA, Rota PA, Icenogle J et al. Expansion of the global measles and rubella laboratory network 2005–09. J. Infect. Dis. 204(Suppl. 1), S491–S498 (2011).
  • Khowaja AR, Sheikh S, Saleem AF, Zaidi AKM. awareness and coverage of mass measles vaccination drive 2011 cross-sectional survey in the metropolitan city of Karachi, Pakistan. Asia Pac. J. Public Health (2012).
  • Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. Br. Med. J. 319, 1462–1467 (1999).
  • Sosa N, Guerra I, Abrego L et al. Successful public health response to four cases of imported measles in Panama. J. Infect. Dev. Ctries. 6(8), 605–610 (2012).
  • De Serres G, Markowski F, Toth E et al. The largest measles epidemic in North America in a decade – Quebec, Canada, 2011: contribution of susceptibility, serendipity and super-spreading events. J. Infect. Dis. 207(6), 990–998 (2013).
  • Hopkins DR. Disease eradication. N. Engl. J. Med. 368, 54–63 (2013).

Websites

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.